[go: up one dir, main page]

BR9915390A - Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas - Google Patents

Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas

Info

Publication number
BR9915390A
BR9915390A BR9915390-4A BR9915390A BR9915390A BR 9915390 A BR9915390 A BR 9915390A BR 9915390 A BR9915390 A BR 9915390A BR 9915390 A BR9915390 A BR 9915390A
Authority
BR
Brazil
Prior art keywords
tumors
growth hormone
compounds
antagonists
administration
Prior art date
Application number
BR9915390-4A
Other languages
English (en)
Inventor
Giampiero Muccioli
Mauro Papotti
Ezio Ghigo
Romano Deghenghi
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of BR9915390A publication Critical patent/BR9915390A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO DE TUMORES ATRAVéS DE ADMINISTRAçãO DE COMPOSTOS QUE LIBERAM HORMÈNIO DE CRESCIMENTO E SEUS ANTAGONISTAS"<D>. Esta invenção refere-se a um método para tratar tumor em mamífero mediante administração de um composto que libera hormónio de crescimento ou um antagonista desse composto, em uma quantidade eficaz para reduzir ou inibir proliferação de células tumorigênicas no mamífero. Em particular, os tumores a serem tratados incluem tumores de pulmão, mamários, de tireóide ou de pâncreas. Os compostos preferidos são certos peptídeos que contêm unidades de metil triptofano e de lisina.
BR9915390-4A 1998-11-16 1999-11-11 Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas BR9915390A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/192,406 US6124263A (en) 1998-11-16 1998-11-16 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
PCT/EP1999/008662 WO2000029011A1 (en) 1998-11-16 1999-11-11 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists

Publications (1)

Publication Number Publication Date
BR9915390A true BR9915390A (pt) 2001-08-07

Family

ID=22709509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915390-4A BR9915390A (pt) 1998-11-16 1999-11-11 Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas

Country Status (30)

Country Link
US (1) US6124263A (pt)
EP (1) EP1131083B1 (pt)
JP (1) JP2002529512A (pt)
KR (1) KR100704138B1 (pt)
CN (3) CN100368014C (pt)
AR (1) AR021286A1 (pt)
AT (1) ATE258062T1 (pt)
BG (1) BG105572A (pt)
BR (1) BR9915390A (pt)
CA (1) CA2350914A1 (pt)
CO (1) CO5140111A1 (pt)
CZ (1) CZ20011577A3 (pt)
DE (1) DE69914365T2 (pt)
DK (1) DK1131083T3 (pt)
ES (1) ES2212650T3 (pt)
HK (1) HK1040934A1 (pt)
HU (1) HUP0104374A3 (pt)
IL (1) IL142858A0 (pt)
MX (1) MXPA01004689A (pt)
NO (1) NO20012367L (pt)
NZ (1) NZ511280A (pt)
PL (1) PL347659A1 (pt)
PT (1) PT1131083E (pt)
RU (1) RU2240133C2 (pt)
SK (1) SK6352001A3 (pt)
TR (1) TR200101350T2 (pt)
TW (2) TWI237565B (pt)
UA (1) UA73100C2 (pt)
WO (1) WO2000029011A1 (pt)
ZA (1) ZA200103182B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
DE10112882A1 (de) * 2001-03-15 2002-09-19 Max Delbrueck Centrum Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren
CA2446857A1 (en) * 2001-05-10 2002-11-14 Queensland University Of Technology Reproductive cancer diagnosis and therapy
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
WO2007127457A2 (en) * 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
CN101541341B (zh) 2006-09-27 2013-06-05 益普生制药两合公司 N末端取代的生长素释放肽类似物
AU2008216789A1 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
US8841257B2 (en) * 2009-04-10 2014-09-23 Board Of Regents, The University Of Texas System Inhibitors of STAT3 and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
IT1399610B1 (it) * 2010-01-28 2013-04-26 Univ Milano Bicocca Uso di agonisti e antagonisti dei recettori per i growth hormone secretagogues per la prevenzione e il trattamento di convulsioni ed epilessia
AU2020218272A1 (en) 2019-02-08 2021-09-02 United States Government As Represented By The Department Of Veterans Affairs Growth hormone-releasing hormone antagonists and uses thereof
JP2022542542A (ja) * 2019-07-18 2022-10-05 ユニバーシティー オブ マイアミ サルコイドーシスを処置する方法での使用のためのｇｈｒｈアンタゴニスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217636B (hu) * 1989-04-26 2000-03-28 Administrators Of The Tulane Educational Fund Szomatosztatin analógok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5385682A (en) * 1990-05-15 1995-01-31 Exxon Research & Engineering Co. Grease composition
MD1591B2 (ro) * 1993-08-09 2001-01-31 Biomeasure, Inc. Derivaţi ai peptidelor cu activitate terapeutică
US5550212A (en) * 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5807985A (en) * 1996-06-11 1998-09-15 Deghenghi; Romano Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
US6063796A (en) * 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists

Also Published As

Publication number Publication date
PT1131083E (pt) 2004-06-30
UA73100C2 (en) 2005-06-15
TWI263642B (en) 2006-10-11
CN1895660A (zh) 2007-01-17
NO20012367D0 (no) 2001-05-14
CN1200726C (zh) 2005-05-11
WO2000029011A1 (en) 2000-05-25
TWI237565B (en) 2005-08-11
CZ20011577A3 (cs) 2002-07-17
TW200530270A (en) 2005-09-16
DE69914365D1 (de) 2004-02-26
KR100704138B1 (ko) 2007-04-09
CN1326353A (zh) 2001-12-12
NO20012367L (no) 2001-07-09
CA2350914A1 (en) 2000-05-25
HUP0104374A2 (hu) 2002-04-29
HUP0104374A3 (en) 2003-03-28
AR021286A1 (es) 2002-07-03
IL142858A0 (en) 2002-03-10
EP1131083B1 (en) 2004-01-21
TR200101350T2 (tr) 2001-11-21
ATE258062T1 (de) 2004-02-15
CN100368014C (zh) 2008-02-13
ES2212650T3 (es) 2004-07-16
US6124263A (en) 2000-09-26
BG105572A (en) 2002-01-31
ZA200103182B (en) 2001-09-07
RU2240133C2 (ru) 2004-11-20
JP2002529512A (ja) 2002-09-10
NZ511280A (en) 2002-10-25
CN1594358A (zh) 2005-03-16
CO5140111A1 (es) 2002-03-22
DE69914365T2 (de) 2004-11-04
PL347659A1 (en) 2002-04-22
HK1040934A1 (zh) 2002-06-28
MXPA01004689A (es) 2002-09-18
DK1131083T3 (da) 2004-04-26
SK6352001A3 (en) 2002-09-10
KR20010089459A (ko) 2001-10-06
CN1277840C (zh) 2006-10-04
EP1131083A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BR0110420A (pt) Agonistas muscarìnicos
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
ATE314062T1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
BR9810911A (pt) Composto, e, processo para tratar câncer em um mamìfero
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
CA2343579A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
EA199901075A1 (ru) Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста
BR0015407A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE69839423D1 (de) Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
DE60028957D1 (de) Pharmazeutische zusammensetzungen enthaltend tetrac sowie deren verwendungsverfahren
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 10A. E 11A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.